Neoadjuvant Durvalumab Plus Chemo Boosts pCR Vs Chemo Alone in Gastric/GEJ Cancers Regardless of Region

Durvalumab plus neoadjuvant FLOT improved pCR vs chemotherapy alone in patients with resectable gastric and GEJ cancers, irrespective of region.

Related Keywords

United States ,America ,Durvalumab Imfinzi ,Merck Serono ,Eli Lilly ,Genentech Roche ,Amerisource Bergen ,Basilea Pharmaceutica ,Yelena Janjigian ,Peerview Institute ,Research To Practice ,Michaelj Hennessy Associates ,Zymeworks Inc ,Guardant Health Inc ,Glaxosmithkline ,Gene Pharma Inc ,Paradigm Medical Communications ,Pfizer ,Lynx Health ,Astrazeneca ,Fred Team ,Department Of Defense ,Bristol Myers Squibb ,Cancers Symposium ,North America ,South America ,Gastrointestinal Oncology Service ,Memorial Sloan Kettering Cancer Center ,Arcus Biosciences ,Ask Gene Pharma ,Clinical Care Options ,Geneos Therapeutics ,Guardant Health ,Mersana Therapeutics ,Silverback Therapeutics ,Durvalumab Plus Standard Neoadjuvant Chemotherapy ,Patients With Resectable Gastric And Gej Cancers ,Matterhorn Trial ,Nct04592913 ,D ,